The new RUO test kits help researchers improve variant detection and viral research. Credit: Roche.

Roche’s newly acquired subsidiary TIB Molbiol has developed three new test kits to detect mutations in the new Omicron variant of Covid-19.

The three new Research Use Only (RUO) test kits include VirSNiP SARS-CoV-2 Spike S371L S373P, VirSNip SARS Spike ins214EPE and VirSNip SARS Spike E484A.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

They are intended to help researchers differentiate the unique mutations in the Omicron variant from other Covid-19 variants.

Roche noted that the VirSNiP variant kits are designed for use on LightCycler and cobas z 480 analysers.

They use quantitative polymerase chain reaction (qPCR) technology to help researchers improve variant detection and viral research.

The new RUO test kits will help evaluate the spread of new Covid-19 variants as well as observe the potential impact of vaccines, public health interventions and therapies on the spread of variants.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Roche Diagnostics CEO Thomas Schinecker said: “The Covid-19 pandemic continues to be an evolving and complex situation, and Roche is committed to responding to healthcare’s biggest challenges.

“The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour.

“There is still much to learn about Omicron. It’s critical to identify Omicron quickly and accurately, which will help inform ongoing research – including the further development of therapeutics and vaccines – and potentially stop or slow down the advance of this new variant.”

The company claims that the VirSNiP variant kits are among the first to detect the new Omicron variant mutations.

After analysing the new Omicron variant’s sequences, Roche has also concluded that all its PCR tests can identify Covid-19 as well as its new variant.

Last month, Roche launched cobas 5800, a new molecular diagnostics system, to expand access to testing and improve patient care.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact